Friends of Cancer Research
Research Company/Group
Friends of Cancer Research is a non-profit cancer research think tank and advocacy organization based in Washington, D.C. Source
Actions
Media Outlet details
| Scope | National |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesAgencyIQ — Eager to leverage prior knowledge, industry pushes FDA to broaden draft guidance’s scope
While stakeholders welcomed the FDA’s recent draft guidance on leveraging prior knowledge, many urged the agency to broaden its recommendations beyond genome editing products. Several also pushed for clarity on how the guidance will connect to other related regulatory concepts, such as the plausible mechanism framework and platform technology designation.
RAPS: Regulatory Focus — Industry asks FDA to expand prior knowledge guidance
Industry stakeholders want the US Food and Drug Administration (FDA) to expand the scope of its recent draft guidance on the types of scientifically valid prior knowledge sponsors may consider when developing gene therapies that involve genome editing to explicitly apply to other types of cell and gene therapies (CGT).
Stakeholder Connect | From Guidance to Action: What Operation TrialBlazer Means for the Future of Oncology Drug Development
In June 2026, the U.S. Department of Health and Human Services (HHS) launched a new initiative called Operation TrialBlazerto “strengthen U.S. leadership in clinical research, accelerate the development of lifesaving treatments, and ensure that patients have access to the most innovative therapies in the world.” This initiative is a department-wide effort across the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Advanced Research Projects Agency for...
The ASCO Post — Two Studies Build Evidence Supporting the Use of ctDNA as an Early Endpoint
Investigators from Friends of Cancer Research (Friends) recently published two manuscripts supporting the use of circulating tumor DNA (ctDNA) as an early endpoint for regulatory decision-making. The first article, published by Andrews et al in the Journal of Liquid Biopsy, aggregated data from randomized clinical trials in the ctMoniTR Project to perform a meta-analysis assessing associations between changes in ctDNA and long-term outcomes.
The Scientist — China Overtakes US in Cancer Drug Approvals
As countries like China ramp up their drug development, US stakeholders will need to explore how to remain competitive in the cancer therapy landscape.
New Friends Publications Build Evidence Supporting the Use of ctDNA as an Early Endpoint
Friends of Cancer Research (Friends) recently published two manuscripts supporting the use of circulating tumor DNA (ctDNA) as an early endpoint for regulatory decision-making. The first article published in the Journal of Liquid Biopsy aggregated randomized clinical trials (RCTs) from the ctMoniTR Project to perform a meta-analysis assessing associations between changes in ctDNA and long-term outcomes.
The Cancer Letter — The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and why
Richard L. Schilsky, H. Kim Lyerly, Thomas R.
Oncology News Central — FDA Moves to Broaden Eligibility for Oncology Clinical Trials
The U.S. Food and Drug Administration (FDA) recently finalized three guidance documents that aim to make clinical trials for oncology drugs more accessible to patients by encouraging sponsors to reconsider eligibility criteria. Issued by the FDA’s Oncology Center of Excellence, the documents address performance status, washout periods, and concomitant medications and laboratory values.
Cancer Network — How Is City of Hope Widening National Clinical Trial Access for Oncology?
City of Hope’s national clinical trials model can activate a study across a network of 40 sites in 4 states within 90 days, according to Edward Kim, MD, MBA.
Stakeholder Connect | Insights from the July 30 Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) Meeting
On July 30, the U.S. Food and Drug Administration (FDA) convened the Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) to consider data intended to support accelerated approval of a regimen combining intratumoral vusolimogene oderparepvec (RP1), a novel oncolytic immunotherapy from Replimune, and systemic nivolumab for adult patients with advanced melanoma who progressed on an anti-PD-1-containing regimen.